Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, Atavistik Bio will leverage its proprietary AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer.
Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug conjugate (ADC) candidate.
Lario Therapeutics Ltd. has divulged voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) blockers reported to be useful for the treatment of neurodegeneration, neurodevelopmental disorders, epilepsy, Parkinson’s disease, endocrine disorders, cerebral vasospasm, pain and epileptic encephalopathy.
Nico Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease and nonalcoholic fatty liver disease (metabolic dysfunction-associated steatotic liver disease [MASLD]).
Unogen Biotech Ltd. has identified triple inhibitors of EGFR (HER1; erbB1), ALK tyrosine kinase receptor and hepatocyte growth factor receptor (HGFR; MET) reported to be useful for the treatment of (non-small-cell) lung cancer.
Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful for the treatment of cancer.
Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition following SARS-CoV-2 infection associated with intestinal manifestations. The most common clinical features include fever, abdominal pain, rash, myocardial dysfunction and elevated inflammatory biomarkers.
RSS
